This study further identified HSP90AA1, ESR1, AKT1, VCAM1, EGFR, CDK1, MAPK1, CDK2, MYC, HSPB1, and HSPA5 as the key targets of YZQX in the treatment of AD with comorbid depression. This evidence concerns the gene CDK1 and depressive symptom measurement.